BRCA2 and ovarian carcinoma: BRCA2-deficient ovarian cancer xenografts showed marked response to olaparib, carboplatin, and olaparib plus carboplatin, whereas BRCA2-proficient xenografts responded only to carboplatin and olaparib plus carboplatin.